• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Accenture Backs Turbine’s AI-Powered Platform to Accelerate Drug Discovery

by Fred Pennic 05/16/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Accenture Ventures, the venture capital arm of Accenture, has announced a strategic investment in Turbine, a company pioneering the use of predictive cell simulations for drug development. 

– The investment aims to empower Turbine in extending its innovative technology to global biopharmaceutical companies seeking to unlock hidden biological insights and accelerate crucial drug development processes.

Optimizing Drug Discovery with Simulated Cells

Turbine’s core technology, the Simulated Cell™ platform, leverages machine learning to decipher human cell decision-making processes. By intricately modeling molecular interactions within and around cells, the platform facilitates virtual experiments on a massive scale, exceeding the capabilities of the physical world. This unveils disease mechanisms and treatment response patterns with unprecedented detail.

Unlocking Hidden Gems: More Effective Treatments

Leading pharmaceutical companies are collaborating with Turbine to validate its platform for several key applications:

  • Identifying Promising Drug Targets: Turbine’s technology helps pinpoint potential targets for drug development, accelerating the discovery of new treatments.
  • Optimizing Patient Selection: By predicting which patients are most likely to benefit from a therapy, Turbine allows for personalized medicine approaches with higher success rates.
  • Developing Effective Combination Therapies: The platform can identify synergistic combinations of therapies, potentially enhancing treatment efficacy for specific patient populations.

Turbine’s capabilities offer the potential to reveal previously unseen treatment possibilities and eliminate drugs that might fail in clinical trials despite showing promise in the lab.

Project Spotlight: Fostering Innovation in Digital Simulations

Turbine joins Accenture Ventures’ Project Spotlight, a program designed to foster collaboration and investment in companies driving disruptive enterprise technology. Project Spotlight grants access to Accenture’s industry expertise and extensive network of clients, empowering startups like Turbine to transform their technology into real-world solutions. Other digital simulation companies within Project Spotlight include QuantHealth, Virtonomy, and Ocean Genomics.

“Since most unsolved complex diseases are heterogenous, progress in utilizing AI for drug discovery is hindered by ethical and technological limitations in sourcing deep and diverse ground truth data. To bridge this gap, we need a toolkit that can learn fundamental rules of biology on in vitro experiments and apply to patients that it has never seen before. Turbine’s Simulated Cells can be engineered at scale to represent the heterogeneity of complex human disease better than currently available wet lab experimental models, which are inherently biased towards representing certain disease types and hardly scalable,” said Szabolcs Nagy, co-founder and CEO of Turbine. “By tapping into Accenture’s expertise, we hope to expand our market reach and augment our simulation platform in order to benefit the whole biopharma industry by ensuring that the next experiment is always the correct one.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Drug Discovery

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |